SUBSTITUIERTE BETA-THIOCARBONSÄUREN

Patent europeic · EP0960096 · Stritgà

Inscripziun en il register

Numer da publicaziun: EP0960096
Numer da la dumonda: EP98900140
Gener: Patent europeic cun effect per la Svizra ed il Liechtenstein
Status: Stritgà
Scrittira da patent: Concedì
Annunzià: 21-01-1998
Publitgà: 01-12-1999
Concedì: 06-04-2005
Stritgà: 20-01-2018
Motiv: Durada maximala cuntanschida
Classas IPC: C07C 317/44 (2006.01)
C07D 333/24 (2006.01)
C07C 317/46 (2006.01)
C07D 317/60 (2006.01)
C07C 317/50 (2006.01)
C07D 209/48 (2006.01)
C07C 323/62 (2006.01)
C07D 215/06 (2006.01)
A61K 31/16 (2006.01)
A61K 31/19 (2006.01)
A61K 31/395 (2006.01)
Prioritad: GB 9701264 22.01.1997
US 41962 P 03.04.1997
Dumonda PCT: PCT/IB1998/000082 21.01.1998
Publicaziun PCT: WO1998/032734 30.07.1998
Derivà da: EP04077217
Lingua da l’annunzia: englais
Funtauna: Swissreg

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

22-01-2018
Durada maximala cuntanschida
Published in Swissreg on 22.01.2018
19-07-2016
Fusiunà
Owner
Aventis Pharmaceuticals Inc., 55 Corporate Drive, Bridgewater New Jersey 08807, USA → Aventisub LLC, 3711 Kennett Pike, Suite 200, Greenville, Delaware 19807, USA
Published in Swissreg on 19.07.2016
04-04-2013
Adressa midada
Owner
Aventis Pharmaceuticals Inc., Route 202-206,, P.O. Box 6800,, Mail Code: EMC-G1, Bridgewater, NJ 08807-0800, USA → Aventis Pharmaceuticals Inc., 55 Corporate Drive, Bridgewater New Jersey 08807, USA
Published in Swissreg on 04.04.2013
15-04-2005
Concedì
Published in +pat+ No 7 in 2005

3711 Kennett Pike, Suite 200, Greenville, Delaware 19807, US